Multiple Sclerosis and Related Disorders

Addressing ethnic diversity in MS trials and research: a multipronged approach 1:50
Addressing ethnic diversity in MS trials and research: a multipronged approach
Mitzi Joi Williams • 25 Feb 2022
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs 3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana • 28 Feb 2022
Evaluation of sNfL in MS patients with NEDA-3 4:19
Evaluation of sNfL in MS patients with NEDA-3
Virginia Meca-Lallana • 28 Feb 2022
Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab 3:33
Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab
Virginia Meca-Lallana • 28 Feb 2022
sNfL activity correlates with MS severity more significantly than cNfL 5:46
sNfL activity correlates with MS severity more significantly than cNfL
Ruturaj Masvekar • 28 Feb 2022
Investigating the role of the gut microbiome in MS progression 2:17
Investigating the role of the gut microbiome in MS progression
Daiki Takewaki • 28 Feb 2022
Validating biomarkers in MS for clinical practice – a large prospective cohort 2:19
Validating biomarkers in MS for clinical practice – a large prospective cohort
Pascal Sati • 26 Feb 2022
Toxic astrogliosis in MS – precision, biomarker-guided combination therapies 10:29
Toxic astrogliosis in MS – precision, biomarker-guided combination therapies
Ruturaj Masvekar • 28 Feb 2022
Diagnostic potential of paramagnetic rim lesions in MS 1:53
Diagnostic potential of paramagnetic rim lesions in MS
Pascal Sati • 26 Feb 2022
Translating MS imaging biomarkers into clinical practice 1:41
Translating MS imaging biomarkers into clinical practice
Pascal Sati • 26 Feb 2022
Lifestyle interventions in MS management 2:58
Lifestyle interventions in MS management
Agne Straukiene • 16 Mar 2022
MS-ReBS: combining visual, radiological, and blood biomarkers for disability prediction in MS 1:39
MS-ReBS: combining visual, radiological, and blood biomarkers for disability prediction in MS
Pascal Sati • 26 Feb 2022
The salivary microbiome as a diagnostic biomarker in MS 6:04
The salivary microbiome as a diagnostic biomarker in MS
Daiki Takewaki • 28 Feb 2022
Clinical and radiological features of NMOSD 2:06
Clinical and radiological features of NMOSD
Amy Kunchok • 25 Feb 2022
The central vein sign in multiple sclerosis 2:13
The central vein sign in multiple sclerosis
Pascal Sati • 26 Feb 2022
Strategies to target progression in MS 2:23
Strategies to target progression in MS
Gavin Giovannoni • 1 Mar 2022
The content of VJNeurology is intended for healthcare professionals